Study recruiting; intended to assess APL-101 monotherapy for NSCLC and solid tumors with various MET alterations and evaluate APL-101 as an add-on to EGFR inhibitors for NSCLC with acquired MET resistance after EGFR treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.